RCKT vs. SRRK, AKRO, ACLX, RYTM, APLS, CRNX, VKTX, IMVT, ACAD, and MTSR
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Scholar Rock (SRRK), Akero Therapeutics (AKRO), Arcellx (ACLX), Rhythm Pharmaceuticals (RYTM), Apellis Pharmaceuticals (APLS), Crinetics Pharmaceuticals (CRNX), Viking Therapeutics (VKTX), Immunovant (IMVT), ACADIA Pharmaceuticals (ACAD), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry.
Rocket Pharmaceuticals vs.
Scholar Rock (NASDAQ:SRRK) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.
Scholar Rock presently has a consensus price target of $40.43, indicating a potential upside of 8.71%. Rocket Pharmaceuticals has a consensus price target of $47.27, indicating a potential upside of 379.44%. Given Rocket Pharmaceuticals' higher possible upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Scholar Rock.
Rocket Pharmaceuticals received 224 more outperform votes than Scholar Rock when rated by MarketBeat users. Likewise, 73.22% of users gave Rocket Pharmaceuticals an outperform vote while only 66.01% of users gave Scholar Rock an outperform vote.
Scholar Rock has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.
Rocket Pharmaceuticals' return on equity of -62.62% beat Scholar Rock's return on equity.
91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 19.2% of Scholar Rock shares are held by company insiders. Comparatively, 28.5% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Rocket Pharmaceuticals had 2 more articles in the media than Scholar Rock. MarketBeat recorded 5 mentions for Rocket Pharmaceuticals and 3 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.58 beat Rocket Pharmaceuticals' score of 0.66 indicating that Scholar Rock is being referred to more favorably in the media.
Scholar Rock has higher revenue and earnings than Rocket Pharmaceuticals. Scholar Rock is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Rocket Pharmaceuticals beats Scholar Rock on 11 of the 17 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RCKT) was last updated on 2/13/2025 by MarketBeat.com Staff